Evidence mapPaperPMID 41322146Full record

ArticleMaterials today. Bio2025

Anti-lung cancer therapy using nano-assembly particles of traditional Chinese Medicine formula.

Yuanfeng Fu, Fei Xia, Lingling Sun, Minyi Guan, Qingchao Tu, Xiangjun Qi, Jigang Wang, Lizhu Lin, Chong Qiu

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuanfeng FuSchool of the First Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China.
Fei XiaState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Lingling SunSchool of the First Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China.
Minyi GuanSchool of the First Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China.
Qingchao TuState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Xiangjun QiSchool of the First Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China.
Jigang WangState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Lizhu LinSchool of the First Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, China.
Chong QiuState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nano-assembly particles (NAPs) isolated from Traditional Chinese Medicine (TCM) formulations retain a better multi-component overall effect than isolated single active ingredient, which gradually emerging as a transformative approach for the pharmacodynamic and pharmacological research of TCM. This study introduced an innovative research paradigm for investigating the mechanisms of TCM formulas and proposes the groundbreaking concept of "TCM nano-formulated prescriptions" using Yi-Fei-San-Jie Formula (YFSJF) as a clinically study model. Firstly, based on the favorable outcomes in 31 clinical patients with pulmonary space-occupying lesions who received YFSJF treatment, the anti-tumor efficacy of NAPs isolated from the YFSJF decoction was systematically evaluated. Furthermore, the basic material components and underlying mechanism of NAPs were elucidated. Finally, 248 artificially synthetic nanoparticles developed by central bioactive components of YFSJF were used to study the self-assembly process, anti-tumor activity and safety profile. This study firstly demonstrated the potential NAPs-based replacement of traditional formulas and establishes a pioneering methodology for screening multi-component NAPs.

Indexed as

Lung cancerNano-assembly particlesTraditional Chinese MedicineYi-Fei-San-Jie formula

Identifiers

PMID41322146
PMCPMC12661425

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.